The Ancillary-Care Obligations of Medical Researchers Working in Developing Countries by 
PLoS Medicine  |  www.plosmedicine.org 0709 May 2008  |  Volume 5  |  Issue 5  |  e90
Guidelines and Guidance
W
herever medical resources are scarce and access 
to medical care is limited, as in most of the 
developing world, medical researchers face difﬁ  cult 
issues about providing medical care beyond the purview of 
their research. In a vaginal microbicide trial enrolling sex 
workers in Benin, for instance, the researchers arranged 
for the sponsors to pay for the care of a participant with an 
extrauterine pregnancy unrelated to the microbicide [1]. In 
a study of tuberculosis preventive regimens for HIV-infected 
adults in Soweto, South Africa, all participants received free 
follow-up HIV care—except for antiretrovirals—as part of the 
protocol (personal communication, R. Chaisson). In these 
cases, working in partnership with local health care providers, 
researchers found ways to provide their study participants 
ancillary care: care that they needed, but that was required 
neither to successfully answer the scientiﬁ  c question nor to 
avoid or mitigate harm resulting from participation in the 
research [2,3]. The researchers’ actions in these cases seem 
admirable, but are they typical? Are they required by the 
ethics of medical research? No one can say, as the issue of 
medical researchers’ ancillary-care obligations has not been 
systematically examined and guidance is lacking. We aim 
to help rectify this lack of guidance by offering a suggested 
framework, focusing on the urgent context of ancillary-care 
needs in the developing world. 
An Increasingly Pressing Issue
With the rise of multidrug-resistant and extensively drug-
resistant tuberculosis, the scaling up of HIV prevention 
trials, the increasing prevalence of chronic diseases as the 
population of developing countries attains a greater average 
age, and the spread of immunosuppression resulting from 
the AIDS epidemic, ancillary-care challenges in developing 
countries will become more prevalent and more difﬁ  cult. 
Yet there are also new opportunities, as such initiatives as the 
Global Fund to Fight AIDS, Tuberculosis and Malaria have 
enhanced the resources available for global health research 
and for the purchase of medicines and other therapies. 
Investigators, organizations, and companies doing medical 
research, both from host and sponsoring countries; those 
normally responsible for the study population’s health 
care; research ethics committees and institutional review 
boards (generically, RECs); and the populations under study 
need guidance about the nature and extent of researchers’ 
ancillary-care obligations. 
Existing Guidance Unsatisfactory
Medical researchers working in developing countries clearly 
cannot meet all of the ancillary health needs of research 
participants, consistently with pursuing their scientiﬁ  c goals. 
Accordingly, some of the broad, positive declarations in 
existing research ethics guidelines ring hollow when applied 
to this issue. For instance, the Declaration of Helsinki states 
that “the health of my patient will be my ﬁ  rst consideration” 
[4]. Physician–researchers who seek to follow this dictum will 
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Summary Points
•  Medical researchers, particularly those working in developing 
countries, as well as their sponsors, have some ancillary-care 
obligations. 
•  Ancillary-care obligations are positive obligations to provide care 
that participants need but that is required neither to successfully 
answer the researchers’ scientiﬁ  c question nor to avoid or 
mitigate harm resulting from participation in the research.
•  The ancillary-care obligations of such researchers and 
their sponsors are not limited to addressing the disease or 
condition that is the target of the research, nor do they center 
on that disease or condition.
•  Existing guidelines for research do not adequately address 
ancillary-care obligations.
•  Consideration of the “four P’s” (positive obligation, 
planning, partnership, and practical steps: Box 1) and of 
“three questions” (of needs, alternatives, and the strength 
of obligation: Box 2) will help to address and direct the 
development of useful guidance.PLoS Medicine  |  www.plosmedicine.org 0710 May 2008  |  Volume 5  |  Issue 5  |  e90
encounter difﬁ  culties when their participants in a medically 
underserved area develop health needs that outstrip the 
research team’s resources or plans; for example, when a rural 
participant in a study of vitamin A deﬁ  ciency is found to have 
cancer treatable only at the tertiary-care hospital in the capital 
of the neighboring country. Taking the Helsinki dictum 
directly to generate ancillary-care obligations would yield 
an unreasonably expansive requirement. Ethics guidelines 
that more speciﬁ  cally address ancillary-care issues are rare. 
It is more common for guidelines to cover the adjacent 
but distinct issues of post-trial availability or “trial-related” 
adverse events [5,6]. An example of sound, but fragmentary, 
guidance on ancillary care may be found in Joint United 
Nations Programme on HIV/AIDS (UNAIDS) Guideline 
16, which calls for “a comprehensive care package” for 
participants of HIV vaccine trials to be agreed upon on a basis 
of “host/community/sponsor dialogue” [7]. This view is also 
taken by the Nufﬁ  eld Council on Bioethics [8]. 
One of the most explicit statements about ancillary care 
is the statement in the Commentary to the Council for 
International Organizations of Medical Sciences’ Guideline 
21 that “although sponsors are, in general, not obliged to 
provide health care services beyond what is necessary for 
the conduct of research, it is morally praiseworthy to do so” 
[5]. This guidance might be interpreted either as implying 
that there is no moral obligation to provide ancillary care 
or simply as indicating that the moral obligation belongs to 
people other than the research team. We agree that these 
obligations may well be best discharged by seeing to it that 
participants get care from others. This means that being 
familiar with local health care resources will itself sometimes 
be morally obligatory, and not merely praiseworthy. 
Dialogue and planning are crucial, but cannot fruitfully 
proceed in a vacuum. As both our experience and anecdotal 
evidence suggest, many researchers and research sponsors 
working in developing countries, as well as their local 
collaborators and the populations under study, strongly feel 
a need for clearer guidance about ancillary care. Leaving 
the moral burden of assessing ancillary-care claims and 
the logistical burden of planning for them in the hands of 
individual principal investigators is unfair, unduly exposing 
them to controversy and to charges of unethical behavior. It 
is also inefﬁ  cient and unlikely to ensure that ancillary care is 
always provided when it should be. 
Whose Responsibility?
Although principal investigators and members of their 
research teams are on the front lines of ancillary care, 
ancillary-care obligations also fall upon the sponsors 
(funders) of medical research. It seems unreasonable to 
assume that researchers who carry out their ancillary-care 
obligations by tending to the urgent ancillary needs of their 
research participants are hijacking resources that ought 
to be devoted solely to research purposes. As we argue 
below, tending to these needs is an integral and necessary 
part of ethical research with human beings. Research 
sponsors should support principal investigators and their 
research teams in carrying out their front-line ancillary-care 
obligations, whether by supplementing study budgets or by 
reinterpreting or easing restrictions on providing care that 
is not “study-related.” Sponsors should not simply respond 
to requests that reach them to provide support for ancillary 
care, but should require that, in any research proposal, 
due attention be paid to deﬁ  ning and costing appropriate 
ancillary-care implications. 
A Middle Position on Ancillary-Care Obligations
Companies and individuals doing medical research in 
developing countries who are able to alleviate the dire effects 
of medical scarcity there have some obligation to address 
the unmet health needs of their study participants, but 
how far does this obligation extend? On one side, we reject 
expansive arguments that would analyze medical researchers’ 
obligations directly in terms of duties to remedy global 
injustice. On the other side, we reject a narrow understanding 
according to which medical researchers, being scientists ﬁ  rst 
and foremost, owe study participants no ancillary care, only 
that medical care needed to bring the research study safely to 
completion. 
One version of the expansive position holds that, the 
world being pervasively unjust, medical researchers from the 
developed world and their sponsors have a duty to do all they 
can to address all of the ancillary-care needs they encounter 
[9,10]. There are four objections to this position. First, 
there is no reason why those engaged in non-exploitative 
medical research—and there are better safeguards in place 
today to prevent exploitation in research than there were 
a decade ago—should bear a greater part of the burden 
of addressing global injustice than does any other citizen 
of the developed countries. Second, medical research in 
general, and in particular much of the medical research 
conducted in developing countries, is directed towards easing 
people’s health burden, which, in the developing world, is 
severe. Meeting all encountered ancillary-care needs would 
strain budgets and monopolize the scarce time of trained 
personnel. Unlimited ancillary-care demands would impose 
heavy costs on medical research and would very likely have 
an inhibitory effect. Therefore, imposing this level of cost 
on the research enterprise is ethically unreasonable. Third, 
if researchers working in developing countries addressed 
all or even most of their participants’ unmet health needs 
via their research studies, that might unduly tempt people 
to enter these studies. While ethical concern with undue 
inducement is sometimes exaggerated, this expansive 
position on ancillary care would distort the incentives of 
potential study participants in an inappropriate way [11]. 
Fourth, were researchers to take on the full range of unmet 
local health needs, they would often be taking on health 
care responsibilities that appropriately belong to the host 
government or local organizations. 
While this expansive position is therefore not acceptable, 
there is a broad consensus that ancillary-care obligations 
are not nil [1,7,8]. Four strong arguments demonstrate 
that medical researchers and their sponsors have positive 
ancillary-care obligations. (1) Due Concern for Welfare: Due 
concern for the welfare of those with whom one interacts 
arguably requires addressing one’s research participants’ 
serious medical needs when one has the capacity to do so 
and they lack other recourse [4]. (2) Rescue: Especially when 
these needs are urgent, a duty of rescue may come into play 
[12]. (3) Justice: While it is not up to medical researchers 
or their sponsors to remedy global injustice in the provision 
of health care, they do encounter many who suffer from 
injustices and have some obligation to do their part in PLoS Medicine  |  www.plosmedicine.org 0711 May 2008  |  Volume 5  |  Issue 5  |  e90
alleviating this suffering, where they are competent to do so 
[13]. (4) Entrustment: While these ﬁ  rst three considerations 
potentially apply to those who are not research participants 
as well as to those who are, there is considerable consensus 
that ancillary-care obligations are specially owed to research 
participants. One way of thinking about this special obligation 
is to take it that, by entering a study or clinical trial, research 
participants automatically entrust certain aspects of their 
health into the researchers’ care [2,3]. 
Each of these arguments—from welfare, rescue, justice, and 
entrustment—demonstrates the existence of strong, positive 
ancillary-care obligations. Given the reasons against the 
expansive position on ancillary care, these positive obligations 
are limited. Concretely working out the extent and limits of 
these obligations requires considerably more work [14,15], 
but here we make a start. 
Unrelated Conditions Covered; “Target” Conditions 
Not Privileged
Whichever arguments supporting researchers’ ancillary-care 
obligations are accepted, it is clear that these obligations 
extend to diseases and conditions unrelated to what is under 
study. The implications of justice are not restricted to the 
target disease alone; neither are the implications of due 
concern for welfare, rescue, or what is effectively entrusted 
to researchers by consenting to participate in certain 
procedures. 
By the same token, none of these arguments specially 
privilege ancillary care for a study’s target disease or 
condition. In emphasizing the importance of considering 
ancillary care for other diseases or conditions, we depart 
from, and seek to go beyond, the approach implicitly taken 
both by a World Health Organization/UNAIDS consultative 
body concerning the ethical considerations related to 
providing care and treatment in vaccine trials [14] and by the 
recently published UNAIDS document on HIV prevention 
trials [16]. The former body, in particular, relied on the 
unfocused argument from justice that we criticized above, 
as well as similarly broad appeals to beneﬁ  cence and to 
reciprocity (“…the ethical principles of justice as equality, 
reciprocity and beneﬁ  cence might be used to justify access 
to care and treatment for trial participants for conditions 
targeted by the vaccine candidate…” [14]). These arguments 
get some traction; but they are not, in their nature, conﬁ  ned 
to medical needs arising from a study’s target disease or 
condition. 
Doing justice, in this context, is complicated. It requires 
being sensitive to whether it is fair to give study participants 
priority over others in need of treatment [17]. Whether 
reciprocity demands post-trial treatment depends on what 
beneﬁ  ts participants may have gotten during a trial. Most 
generally, while maximizing beneﬁ  t to those participants 
who are in need may require providing them with necessary 
care, participants in other trials may have needs that are 
more urgent than those arising from the target disease or 
condition. 
While talk of a “target disease” tends to suggest 
interventional trials, ancillary-care obligations also arise 
in observational and epidemiological studies [18]. For 
example, in Kenya, a non-interventional study of pregnant 
women investigated the effect of maternal infection or 
immunity to various parasitic diseases (such as malaria and 
schistosomiasis) on their babies. Relying on published studies 
of women visiting antenatal clinics in this area, a 30% HIV 
prevalence rate was expected among study participants. 
On this basis, it was calculated that administering single-
dose nevirapine (then otherwise difﬁ  cult to obtain) would 
prevent 11–20 HIV infections among the babies born to 
study participants (personal communication, L. Higgs). Due 
concern for the babies’ welfare gave these researchers and 
research sponsors compelling moral reasons for providing 
nevirapine as ancillary care for this non-target disease. 
Some ancillary-care needs can be readily foreseen and 
planned for. In certain areas of the world, for example, 
researchers studying children with malaria will know to 
expect that a signiﬁ  cant percentage of these children will also 
be infected with schistosomiasis and that carrying out study 
procedures might well reveal this comorbidity. They should 
arrange for any children they diagnose with schistosomiasis 
to receive antihelminthic agents. In some cases, diagnosis 
Box 1. Three Questions for RECs Assessing Human 
Studies in Developing Countries
1. Needs: What ancillary-care needs, if any, are likely to be 
encountered? 
  •  What is the health burden of the host population 
  (locally endemic diseases, local disease prevalence and  
 incidence,  etc.)?
  •  Are the study procedures likely to reveal concurrent   
  diseases or conditions that will need to be addressed?
2. Alternatives: Can identiﬁ  ed ancillary-care needs be met by the 
existing local health system?
  •  What existing health care facilities and opportunities,  
  especially for treatment of locally endemic conditions, are  
  reasonably accessible to study participants?
  •  To what extent is the existing local health infrastructure  
  already overburdened and local trained medical personnel  
 scarce?
3. Obligations: How strong is the responsibility of researchers 
and their sponsors to address the ancillary-care needs they 
identify in this study?
  •  How severe or acute are the likely ancillary-care needs,  
  and what would be the consequences, for individual study  
  participants, were these needs to go unmet?
  •  Is the identiﬁ  cation of ancillary-care needs in this study likely 
  to be integral or incidental to carrying out study    
 procedures? 
  •  What is the duration of the study and how extensive are  
  the proposed interactions between researchers and study  
 participants?
  •  Is the research study part of a broader set of studies that  
  these researchers or their sponsors are conducting, or aim  
  to conduct, with this host population?
  •  What are the foreseeable costs of providing ancillary care,  
  in funds, personnel time, and potential interference with the  
 study’s  scientiﬁ  c aims?
  •  What is the nature and identity of investigators’ and funders’ 
  institutions, and to what extent would they be able to  
  support the provision of ancillary care?PLoS Medicine  |  www.plosmedicine.org 0712 May 2008  |  Volume 5  |  Issue 5  |  e90
of ancillary conditions is not only foreseeable, but integral 
to a study’s design. For instance, a trial of a drug to treat 
cryptosporidial diarrhea in children might ﬁ  rst administer 
HIV tests to the children and then stratify them on the basis 
of their HIV status [19]. The protocol of such a trial should 
include a plan for the ongoing management or referral of the 
children identiﬁ  ed as being HIV infected.
Review by Research Ethics Committees
Because research protocols, especially those involving 
developing-country participants, should outline how they 
will address participants’ ancillary-care needs [16], RECs 
reviewing these protocols should assess the investigators’ 
stated plans for meeting anticipated ancillary-care needs. 
Research studies and their contexts vary so radically, and in 
ways that affect ancillary-care obligations, that protocol-by-
protocol review is essential. An observational study involving 
only a single assessment of each participant, for instance, 
raises very different issues than a long-term interventional 
trial. Existing RECs are a well-established mechanism for 
ethics review of research studies. Examination of ancillary-
care issues should be integral to their review. Because 
the issue of ancillary care has not been explicitly raised 
until recently, it is not known to what extent RECs have 
been addressing ancillary-care issues already. Asking these 
committees—especially those in host countries—to examine 
ancillary-care issues may impose a further burden on them. 
Their capacity will need to be enhanced, an effort that 
international sponsors of research should support. Local 
RECs are well placed to consider speciﬁ  c local factors, which 
matter more to ancillary-care issues than to some other issues 
of research ethics; but in considering these factors they will 
need to draw on the advice and support of the international 
medical research community. 
In reviewing each proposed research study involving 
developing-country participants, RECs should consider 
the three questions set out in Box 1, which address the 
contextually variable features that bear on ancillary-care 
needs and obligations in an important way [15]. 
Guidelines and Policies Needed 
Just as individual research teams should not have to shoulder, 
unaided, the moral burden of determining the boundaries of 
their ancillary-care obligations, so too do RECs deserve some 
general ethical guidance on ancillary-care issues. Because of 
the contextual variability just noted, this guidance should 
take the form not of speciﬁ  c rules but of general guidelines. 
These guidelines should be developed in tandem with 
policies and guidance addressed to research sponsors, and 
they should be international, so as to minimize the danger 
that a country’s stringent ancillary-care standards would cause 
research studies to locate elsewhere. While fully establishing 
the content of any ancillary-care guidance obviously must 
await further debate, discussion, and experience, we suggest 
that any adequate guidance must contain, in addition to the 
framework of the three questions set out in Box 1, the four 
points (“the four P’s”) described in Box 2.
Unintended Consequences
We propose these three questions and “four Ps” of minimal 
ancillary-care guidance as a necessary start. We recognize 
that any guidance that can be seen as adding requirements 
may have unintended consequences, some of which can 
be foreseen. One concern is the additional paperwork 
demanded of researchers and the additional attention 
demanded of REC members in what is already a difﬁ  cult 
process. This we view as an unavoidable downside of 
allocating the moral burden of ancillary-care determinations 
more fairly and efﬁ  ciently. A second concern is that the 
ﬁ  nancial and logistical burden on researchers of providing 
ancillary care may further inhibit research in developing 
countries, in particular, research on such relatively neglected 
conditions as Chagas disease and leishmaniasis. Any 
guidelines should be sensitive to this danger, and should 
also consider how international ancillary-care standards may 
burden researchers based in developing countries. A third 
concern is the possible disruption of local efforts to improve 
health care conditions. Such disruption can happen for very 
different reasons: because researchers’ provision of care 
takes the pressure off of local governments to provide it, for 
example, or because researchers divert scarce local medical 
talent. RECs should do their best to address this kind of 
concern. 
Conclusion
We have offered some guidelines, but more debate and 
analysis of the grounds for and extent of researchers’ 
ancillary-care obligations is needed at the conceptual level. 
Many difﬁ  cult issues, such as how to characterize the standard 
of care appropriate in providing ancillary care, remain to be 
addressed. Empirical research about researchers and research 
participants’ attitudes, perceptions, and expectations, as 
well as about current ancillary-care practices, should be 
Box 2. Four Guidance Points on Ancillary-Care 
Obligations (“The Four P’s”)
1. Positive duty: Researchers and research sponsors, especially 
those working in developing countries, have some positive 
moral obligation to provide some ancillary care to their study 
participants (or to see to it that their participants receive such 
care).
2. Planning: Researchers and research sponsors, especially 
those working in developing countries, consequently should 
develop plans, both in general and for each protocol, for 
meeting the ancillary-care obligations that may be expected 
to arise. They should also take account of the unpredictable 
nature of ancillary-care needs and plan accordingly. 
3. Partnership: These ancillary-care plans should be developed 
in dialogue and partnership with the host community, in 
ways that maintain respectful interaction, avoid displacing 
or disrupting local health care structures, and represent 
the population of potential study participants, community 
advisory boards, and the local medical community. 
4. Practical provisions: Where they have foreseeable 
ancillary-care obligations, researchers and research sponsors 
should take deﬁ  nite practical steps towards meeting these 
obligations. This might mean hiring a physician with certain 
competencies as part of the local study team; setting aside 
a certain line item or percentage of the budget; or forming 
partnerships with those who can provide drugs or with 
development agencies that can aid in improving the local 
infrastructure. PLoS Medicine  |  www.plosmedicine.org 0713 May 2008  |  Volume 5  |  Issue 5  |  e90
undertaken to inform the debate and the development of 
appropriate guidelines.   
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